Glimpse Of New Phase III Data Hints Pfizer's Eagerly-Awaited Oral RA Drug Is Still On Track
This article was originally published in The Pink Sheet Daily
Executive Summary
JAK inhibitor tofacitinib, formerly called tasocitinib, meets primary endpoints in second Phase III study, could be filed in second half of 2011.